Cargando…

Association of CCL4 rs10491121 and rs1634507 gene polymorphisms with cancer susceptibility: trial sequential analysis and meta-analysis

BACKGROUND: Although numerous case-control studies have explored the association between CC cytokine ligand-4 (CCL4) expression and cancer susceptibility, their results have been conflicting. This study aimed to determine the still-unknown connection of CCL4 rs10491121 and rs163450 polymorphisms wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Changsen, Song, Tiangang, Mo, Yajie, Wu, Peixuan, Tian, Haokun, Wen, Lequan, Gao, Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430776/
https://www.ncbi.nlm.nih.gov/pubmed/37593100
http://dx.doi.org/10.3389/fonc.2023.1133055
_version_ 1785091044090576896
author Yang, Changsen
Song, Tiangang
Mo, Yajie
Wu, Peixuan
Tian, Haokun
Wen, Lequan
Gao, Yun
author_facet Yang, Changsen
Song, Tiangang
Mo, Yajie
Wu, Peixuan
Tian, Haokun
Wen, Lequan
Gao, Yun
author_sort Yang, Changsen
collection PubMed
description BACKGROUND: Although numerous case-control studies have explored the association between CC cytokine ligand-4 (CCL4) expression and cancer susceptibility, their results have been conflicting. This study aimed to determine the still-unknown connection of CCL4 rs10491121 and rs163450 polymorphisms with cancer susceptibility. METHODS: Several databases, such as Web of Science, PubMed, and EMBASE, were searched for papers published since the creation of the database until November 2, 2022. Using RevMan 5.4 and StataMP 17 softwares, meta-analysis and subgroup analysis were performed after article screening and data extraction. For sensitivity analyses, one-by-one exclusion method was used, and then, the comprehensive effect was estimated and compared with that before exclusion. Trial sequential analysis (TSA)was performed using TSA 0.9.5.10 beta software. RESULTS: Seven case-control studies encompassing 3559 cases and 4231 controls were included. The P value was greater than 0.05 for all models, indicating the absence of an evident relationship of CCL4 gene rs10491121 and rs1634507 polymorphisms with cancer susceptibility. However, in the subgroup analysis of rs10491121, the P values in all models studied by us except GA vs. AA were <0.05 considering the Chinese subgroup, suggesting that the G allele is a risk factor for cancer in the Chinese population. Besides, in the subgroup analysis of rs1634507 considering oral cancer, the co-dominant model GG vs. TT, dominant model GG + GT vs. TT, and allele model G vs. T groups showed OR < 1 and P < 0.05, indicating that the G allele was a protective factor of oral cancer. However, for other cancer types, all the models studied by us except GG vs. GT showed OR > 1 and P < 0.05, indicating that the G allele was a risk factor for these other cancers. Despite the statistically significant results, sensitivity analysis had some stability limitations, and TSA results suggested the possibility of false positives. CONCLUSION: For rs10491121, we identified an association between the G allele and increased cancer risk in the Chinese population. For rs1634507, the G allele was not found to be associated with reduced risk of oral cancer and increased risk of other cancers studied by us.
format Online
Article
Text
id pubmed-10430776
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104307762023-08-17 Association of CCL4 rs10491121 and rs1634507 gene polymorphisms with cancer susceptibility: trial sequential analysis and meta-analysis Yang, Changsen Song, Tiangang Mo, Yajie Wu, Peixuan Tian, Haokun Wen, Lequan Gao, Yun Front Oncol Oncology BACKGROUND: Although numerous case-control studies have explored the association between CC cytokine ligand-4 (CCL4) expression and cancer susceptibility, their results have been conflicting. This study aimed to determine the still-unknown connection of CCL4 rs10491121 and rs163450 polymorphisms with cancer susceptibility. METHODS: Several databases, such as Web of Science, PubMed, and EMBASE, were searched for papers published since the creation of the database until November 2, 2022. Using RevMan 5.4 and StataMP 17 softwares, meta-analysis and subgroup analysis were performed after article screening and data extraction. For sensitivity analyses, one-by-one exclusion method was used, and then, the comprehensive effect was estimated and compared with that before exclusion. Trial sequential analysis (TSA)was performed using TSA 0.9.5.10 beta software. RESULTS: Seven case-control studies encompassing 3559 cases and 4231 controls were included. The P value was greater than 0.05 for all models, indicating the absence of an evident relationship of CCL4 gene rs10491121 and rs1634507 polymorphisms with cancer susceptibility. However, in the subgroup analysis of rs10491121, the P values in all models studied by us except GA vs. AA were <0.05 considering the Chinese subgroup, suggesting that the G allele is a risk factor for cancer in the Chinese population. Besides, in the subgroup analysis of rs1634507 considering oral cancer, the co-dominant model GG vs. TT, dominant model GG + GT vs. TT, and allele model G vs. T groups showed OR < 1 and P < 0.05, indicating that the G allele was a protective factor of oral cancer. However, for other cancer types, all the models studied by us except GG vs. GT showed OR > 1 and P < 0.05, indicating that the G allele was a risk factor for these other cancers. Despite the statistically significant results, sensitivity analysis had some stability limitations, and TSA results suggested the possibility of false positives. CONCLUSION: For rs10491121, we identified an association between the G allele and increased cancer risk in the Chinese population. For rs1634507, the G allele was not found to be associated with reduced risk of oral cancer and increased risk of other cancers studied by us. Frontiers Media S.A. 2023-08-01 /pmc/articles/PMC10430776/ /pubmed/37593100 http://dx.doi.org/10.3389/fonc.2023.1133055 Text en Copyright © 2023 Yang, Song, Mo, Wu, Tian, Wen and Gao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Yang, Changsen
Song, Tiangang
Mo, Yajie
Wu, Peixuan
Tian, Haokun
Wen, Lequan
Gao, Yun
Association of CCL4 rs10491121 and rs1634507 gene polymorphisms with cancer susceptibility: trial sequential analysis and meta-analysis
title Association of CCL4 rs10491121 and rs1634507 gene polymorphisms with cancer susceptibility: trial sequential analysis and meta-analysis
title_full Association of CCL4 rs10491121 and rs1634507 gene polymorphisms with cancer susceptibility: trial sequential analysis and meta-analysis
title_fullStr Association of CCL4 rs10491121 and rs1634507 gene polymorphisms with cancer susceptibility: trial sequential analysis and meta-analysis
title_full_unstemmed Association of CCL4 rs10491121 and rs1634507 gene polymorphisms with cancer susceptibility: trial sequential analysis and meta-analysis
title_short Association of CCL4 rs10491121 and rs1634507 gene polymorphisms with cancer susceptibility: trial sequential analysis and meta-analysis
title_sort association of ccl4 rs10491121 and rs1634507 gene polymorphisms with cancer susceptibility: trial sequential analysis and meta-analysis
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430776/
https://www.ncbi.nlm.nih.gov/pubmed/37593100
http://dx.doi.org/10.3389/fonc.2023.1133055
work_keys_str_mv AT yangchangsen associationofccl4rs10491121andrs1634507genepolymorphismswithcancersusceptibilitytrialsequentialanalysisandmetaanalysis
AT songtiangang associationofccl4rs10491121andrs1634507genepolymorphismswithcancersusceptibilitytrialsequentialanalysisandmetaanalysis
AT moyajie associationofccl4rs10491121andrs1634507genepolymorphismswithcancersusceptibilitytrialsequentialanalysisandmetaanalysis
AT wupeixuan associationofccl4rs10491121andrs1634507genepolymorphismswithcancersusceptibilitytrialsequentialanalysisandmetaanalysis
AT tianhaokun associationofccl4rs10491121andrs1634507genepolymorphismswithcancersusceptibilitytrialsequentialanalysisandmetaanalysis
AT wenlequan associationofccl4rs10491121andrs1634507genepolymorphismswithcancersusceptibilitytrialsequentialanalysisandmetaanalysis
AT gaoyun associationofccl4rs10491121andrs1634507genepolymorphismswithcancersusceptibilitytrialsequentialanalysisandmetaanalysis